Abstracts tagged "Biologicals"

Abstract Number: 0349 • ACR Convergence 2020
Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
Christopher Ritchlin¹, Proton Rahman², Philip Helliwell³, Wolf-Henning Boehncke⁴, Iain McInnes⁵, Alice Gottlieb⁶, Shelly Kafka⁷, Alexa Kollmeier⁸, Elizabeth Hsia⁹, Xie Xu¹⁰, May Shawi¹¹, Shihong Sheng¹², Prasheen Agarwal¹², Bei Zhou¹², Paraneedharan Ramachandran¹³ and Philip Mease¹⁴, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ¹⁰Janssen Research & Development, LLC, San Marcos, CA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Janssen Research & Development, LLC, Horsham, ¹⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2, two double-blind, phase 3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs…
Abstract Number: 0458 • ACR Convergence 2020
Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force
Bibi Ayesha¹, Anand Kumthekar¹, Ruchi Jain², Sneha Patel³, Manish Ramesh¹, Denisa Ferastraoaru⁴, Golda Hudes⁴, Merhunisa Karagic⁴, Sheema Zafar¹, Rachel Bartash⁴, Natalia Vasquez-Canizares⁵, Elizabeth Kitsis⁶, Clement Tagoe⁷, Dawn Wahezi⁵, Tamar Rubinstein⁸ and Anna Broder³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center, Irvington, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁴Montefiore Medical Center, Bronx, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Fresh Meadows, NY, ⁸Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Coronavirus disease (COVID-19) infected patients present with a state of ongoing inflammation and an exaggerated inflammatory state due to unregulated cytokine release called the…
Abstract Number: 0638 • ACR Convergence 2020
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
Cristobal Pavez Perales¹, Samuel Leal Rodriguez², Marta De la Rubia Navarro¹, Roxana Gonzalez Mazario¹, Elena Grau Garcia³, Cristina Alcañiz Escandell³, Inmaculada Chalmeta Verdejo¹, Jorge Juan Fragio Gil¹, Luis Gonzalez Puig⁴, Jose Ivorra Cortes¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁵, Elvira Vicens Bernabeu² and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department, HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain, ⁵La Fe University Hospital, Valencia
Background/Purpose: In mid-March 2020, state of alarm was declared in Spain due to the novel coronavirus disease 2019 (COVID-19) pandemic. Patients with rheumatic diseases (RD)…
Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Rishi Gupta¹, Muhammad Shipa², Su-Ann Yeoh², Pauline Buck¹ and Michael Ehrenstein², ¹University College London Hospital, London, United Kingdom, ²University College London, LONDON, United Kingdom
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…
Abstract Number: 0894 • ACR Convergence 2020
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
Stanley Cohen¹, Justus Fiechtner², Philip Mease³, Jeffrey Kaine⁴, Arthur Kavanaugh⁵, Yi-Lin (Irene) Cheng⁶, Claire Chou⁶, Ting-Ying Cheng⁷, Shih-Yao Lin⁶ and Mark Genovese⁸, ¹University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ²Michigan State University, Grand Rapids,, MI, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Sarasota Arthritis Research Center, Sapphire, NC, ⁵UC San Diego Health System, San Diego, CA, ⁶AltruBio, Taipei, Taiwan (Republic of China), ⁷AltruBio, Redwood City, CA, ⁸Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.…
Abstract Number: 1207 • ACR Convergence 2020
Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial
DaeHyun Yoo¹, Rene Westhovens², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, NooRi Han⁹ and YooBin Jung⁹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²University Hospitals Leuven, Belgium, Leuven, Belgium, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: In the analysis of PLANETRA, a Phase III randomized controlled trial (RCT), no significant association was found between body mass index (BMI) and clinical…
Abstract Number: 1364 • ACR Convergence 2020
Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
Xenofon Baraliakos¹, Atul Deodhar², Maxime Dougados³, Marga Oortgiesen⁴, Natasha de Peyrecave⁵, Martin Bauer⁶, Thomas Vaux⁵, Carmen Fleurinck⁷ and Désirée van der Heijde⁸, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Oregon Health & Science University, Portland, OR, ³Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Bimekizumab (BKZ), a monoclonal antibody that selectively inhibits interleukin (IL)-17A and IL-17F, has demonstrated clinical efficacy in patients with ankylosing spondylitis (AS) treated over…
Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Mark Lebwohl¹, Darren West², Alan Mendelsohn³, Stephen Rozzo³ and Giampiero Girolomoni⁴, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Spectrum Dermatology, Scottsdale, AZ, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
Abstract Number: 2025 • ACR Convergence 2020
Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
Philip Mease¹, Philip Helliwell², Dafna Gladman³, Denis Poddubnyy⁴, Xenofon Baraliakos⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Elizabeth Hsia⁸, Xie Xu⁹, Shihong Sheng¹⁰, Prasheen Agarwal¹⁰, Bei Zhou¹⁰, May Shawi¹¹, Chetan Karyekar¹², Kristen Sweet¹⁰, Atul Deodhar¹³ and Désirée van der Heijde¹⁴, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁹Janssen Research & Development, LLC, San Marcos, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Global Services, LLC, Horsham, PA, ¹³Oregon Health & Science University, Portland, OR, ¹⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Guselkumab (GUS), an interleukin-23 inhibitor, improved axial symptoms of active psoriatic arthritis (PsA) through week 24 in a pooled analysis from two phase 3…
Abstract Number: 0218 • ACR Convergence 2020
Clinical Outcomes of Earlier versus Delayed Treatment of Iraqi Patients with Rheumatoid Arthritis with Etanercept
Nizar Abdulateef¹, Faiq Gorial¹, Yasameen Humadi², Dina Yasiry³, Fadya Al Derwibee³, Nancy Sunna⁴ and Ali AlJabban⁵, ¹Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ²Baghdad Teaching Hospital, Rheumatology Department, Baghdad, Iraq, Baghdad, Iraq, ³Baghdad Teaching Hospital, Rheumatology Department, Baghdad, Iraq, Baghdad, Iraq, ⁴Pfizer Inc., Amman, Jordan, ⁵Pfizer Inc., Baghdad, Iraq
Background/Purpose: The management of patients with early rheumatoid arthritis (RA), defined by the American College of Rheumatology (ACR) guidelines as patients who have had RA…
Abstract Number: 0350 • ACR Convergence 2020
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Atul Deodhar¹, Philip Mease², Paula Machado³, Effie Pournara⁴, Xiangyi Meng³, Vibeke Strand⁵ and Marina Magrey⁶, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease involving the sacroiliac joints and spine and associated with pain, stiffness, and disability.1 A previous analysis…
Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Marianna Frey¹, Gregory Vitone², Candace Feldman³, Lindsay Lally¹, Anne Bass⁴, Jane Salmon¹, Mary Crow¹, Michael Lockshin⁵, Vivian Bykerk¹, Lisa Mandl¹ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Brigham and Women's Hospital, Boston, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…
Abstract Number: 0642 • ACR Convergence 2020
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
Marta González Fernández¹, Orlando Pompei fernández², Joaquín María Belzunegui Otano³, Paula García Escudero¹, Claudia Stoye², Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Jakub Závada¹ and Lucie Nekvindova², ¹Revmatologický ústav, Praha 2, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…
Abstract Number: 0897 • ACR Convergence 2020
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
Xenofon Baraliakos¹, Annette Szumski², Kenneth Kwok³ and Bonnie Vlahos⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Syneos Health, Princeton, ³Pfizer, New York, NY, ⁴Pfizer, Collegeville, PA
Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].